ערך בספרים למניה: longboardpharma.com (LBPH)

Longboard Pharmaceuticals focuses on epilepsy therapy, relying on Bexicaserin trials and external funding. The reported book value per share demonstrates financial stability, and 7.12 captures the magnitude of this parameter. Longboard Pharmaceuticals is attracting leading neurobiologists to develop innovative drugs. The current ecosystem relies on FDA support and the influx of investment following successful clinical trial phases.

Capital analysis allows for the filtering of speculative noise by revealing the actual value of net assets minus liabilities, which reflects the fundamental book value of a common share. For Longboard Pharmaceuticals (LBPH), which is developing drugs for severe epilepsy, the trend of this indicator confirms the financial stability of the business during its active growth phase and determines a fair entry threshold without overpaying for assets.